{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:48:07Z","timestamp":1794642487077,"version":"4.9.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.diabres.2022.109212","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T11:19:23Z","timestamp":1642677563000},"page":"109212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Glycated albumin and HbA1c as markers of lower extremity disease in US adults with and without diabetes"],"prefix":"10.1016","volume":"184","author":[{"given":"Caitlin W.","family":"Hicks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Christenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Selvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2022.109212_b0005","article-title":"Peripheral Neuropathy and All-Cause and Cardiovascular Mortality in U.S. Adults : A Prospective Cohort Study","author":"Hicks","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2022.109212_b0010","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2337\/diacare.22.7.1029","article-title":"Lower-extremity amputation in diabetes. The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers","volume":"22","author":"Adler","year":"1999","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.diabres.2022.109212_b0015","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/ATVBAHA.120.314595","article-title":"Epidemiology and Risk of Amputation in Patients With Diabetes Mellitus and Peripheral Artery Disease","volume":"40","author":"Barnes","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabres.2022.109212_b0020","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2337\/diacare.27.7.1591","article-title":"Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999\u20132000 national health and nutrition examination survey","volume":"27","author":"Gregg","year":"2004","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.diabres.2022.109212_b0025","doi-asserted-by":"crossref","first-page":"722","DOI":"10.2337\/dc20-1743","article-title":"Temporal Trends in Incident Hospitalization for Diabetes-Related Foot Ulcer in Type 2 Diabetes: The Fremantle Diabetes Study","volume":"44","author":"Hamilton","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2022.109212_b0030","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.atherosclerosis.2018.04.042","article-title":"Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study","volume":"274","author":"Ding","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabres.2022.109212_b0035","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2337\/diacare.29.04.06.dc05-2018","article-title":"HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study","volume":"29","author":"Selvin","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2022.109212_b0040","doi-asserted-by":"crossref","unstructured":"Hicks CW, Wang D, Daya NR, Windham BG, Ballantyne CM, Matsushita K, et al. Associations of Cardiac, Kidney, and Diabetes Biomarkers With Peripheral Neuropathy among Older Adults in the Atherosclerosis Risk in Communities (ARIC) Study. Clin Chem 2020; 66:686-696.","DOI":"10.1093\/clinchem\/hvaa051"},{"issue":"5","key":"10.1016\/j.diabres.2022.109212_b0045","doi-asserted-by":"crossref","first-page":"894","DOI":"10.2337\/diacare.25.5.894","article-title":"UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes","volume":"25","author":"Adler","year":"2002","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.diabres.2022.109212_b0050","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.amjmed.2003.09.038","article-title":"Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men","volume":"116","author":"Al-Delaimy","year":"2004","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.diabres.2022.109212_b0055","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/08990220.2020.1830757","article-title":"Association of disease duration and sensorimotor function in type 2 diabetes mellitus: beyond diabetic peripheral neuropathy","volume":"37","author":"Khan","year":"2020","journal-title":"Somatosens Mot Res"},{"issue":"12","key":"10.1016\/j.diabres.2022.109212_b0060","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/dme.13514","article-title":"Association between HbA1c and peripheral neuropathy in a 10-year follow-up study of people with normal glucose tolerance, impaired glucose tolerance and Type 2 diabetes","volume":"34","author":"Peterson","year":"2017","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.diabres.2022.109212_b0065","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-018-0693-0","article-title":"HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients","volume":"17","author":"Su","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.diabres.2022.109212_b0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1056-8727(95)00086-0","article-title":"Diabetic peripheral neuropathy: effects of age, duration of diabetes, glycemic control, and vascular factors","volume":"11","author":"Valensi","year":"1997","journal-title":"J Diabetes Complications"},{"issue":"6","key":"10.1016\/j.diabres.2022.109212_b0075","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00592-016-0900-y","article-title":"Glycated albumin indicates peripheral diabetic neuropathy","volume":"53","author":"Wang","year":"2016","journal-title":"Acta Diabetol"},{"issue":"3","key":"10.1016\/j.diabres.2022.109212_b0080","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.diabres.2007.01.005","article-title":"Prevalence of lower extremity diseases associated with normal glucose levels, impaired fasting glucose, and diabetes among U.S. adults aged 40 or older","volume":"77","author":"Gregg","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2022.109212_b0085","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care 2010; 33 Suppl 1:S11-61.","DOI":"10.2337\/dc10-S011"},{"key":"10.1016\/j.diabres.2022.109212_b0090","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1046\/j.1464-5491.2003.01065.x","article-title":"Diabetes control and complications: the role of glycated haemoglobin, 25 years on","volume":"21","author":"Jeffcoate","year":"2004","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.diabres.2022.109212_b0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1507\/endocrj.K06-103","article-title":"Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control","volume":"54","author":"Takahashi","year":"2007","journal-title":"Endocr J"},{"key":"10.1016\/j.diabres.2022.109212_b0100","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1007\/s11892-014-0548-3","article-title":"Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management","volume":"14","author":"Parrinello","year":"2014","journal-title":"Curr Diab Rep"},{"issue":"10","key":"10.1016\/j.diabres.2022.109212_b0105","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.2337\/dci21-0035","article-title":"Hemoglobin A1c-Using Epidemiology to Guide Medical Practice: Kelly West Award Lecture 2020","volume":"44","author":"Selvin","year":"2021","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.diabres.2022.109212_b0110","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00125-020-05285-3","article-title":"Glycaemic markers and all-cause mortality in older adults with and without diabetes: the Atherosclerosis Risk in Communities (ARIC) study","volume":"64","author":"Rooney","year":"2021","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.diabres.2022.109212_b0115","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S2213-8587(13)70199-2","article-title":"Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study","volume":"2","author":"Selvin","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.diabres.2022.109212_b0120","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.115.015415","article-title":"Fructosamine and Glycated Albumin and the Risk of Cardiovascular Outcomes and Death","volume":"132","author":"Selvin","year":"2015","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.diabres.2022.109212_b0125","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.3390\/jcm9113634","article-title":"Recent Updates and Advances in the Use of Glycated Albumin for the Diagnosis and Monitoring of Diabetes and Renal, Cerebro- and Cardio-Metabolic Diseases","volume":"9","author":"Giglio","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.diabres.2022.109212_b0130","doi-asserted-by":"crossref","unstructured":"Selvin E, Warren B, He X, Sacks DB, Saenger AK. Establishment of Community-Based Reference Intervals for Fructosamine, Glycated Albumin, and 1,5-Anhydroglucitol. Clin Chem 2018; 64:843-850.","DOI":"10.1373\/clinchem.2017.285742"},{"key":"10.1016\/j.diabres.2022.109212_b0135","doi-asserted-by":"crossref","unstructured":"Daya NR, Rooney MR, Tang O, Coresh J, Christenson RH, Selvin E. Glycated Albumin in Pristine and Non-Pristine Stored Samples in the National Health and Nutrition Examination Survey (NHANES) 1999-2004. J Appl Lab Med 2022.","DOI":"10.1093\/jalm\/jfab168"},{"key":"10.1016\/j.diabres.2022.109212_b0140","unstructured":"Centers for Disease Control and Preventions. About the National Health and Nutrition Examination Survey. 2017. Accessed 08\/03\/2021. https:\/\/www.cdc.gov\/nchs\/nhanes\/about_nhanes.htm."},{"key":"10.1016\/j.diabres.2022.109212_b0145","unstructured":"Centers for Medicare and Medicaid Services. National Health and Nutrition Examination Survey 1999-2000 Data Documentation, Codebook, and Frequencies: Lower Extremity Disease - Peripheral Neuropathy (LEXPN). 2002. https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/1999-2000\/LEXPN.htm."},{"issue":"10","key":"10.1016\/j.diabres.2022.109212_b0150","doi-asserted-by":"crossref","first-page":"107638","DOI":"10.1016\/j.jdiacomp.2020.107638","article-title":"Glycemic control and diabetic foot ulcer outcomes: A systematic review and meta-analysis of observational studies","volume":"34","author":"Lane","year":"2020","journal-title":"J Diabetes Complications"},{"issue":"2","key":"10.1016\/j.diabres.2022.109212_b0155","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/1534734615593190","article-title":"HbA1c and Lower Extremity Amputation Risk in Patients With Diabetes: A Meta-Analysis","volume":"14","author":"Zhou","year":"2015","journal-title":"Int J Low Extrem Wounds"},{"issue":"1","key":"10.1016\/j.diabres.2022.109212_b0160","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/diseases9010016","article-title":"Glycated Hemoglobin (HbA1c) as a Biomarker for Diabetic Foot Peripheral Neuropathy","volume":"9","author":"Casadei","year":"2021","journal-title":"Diseases"},{"issue":"1","key":"10.1016\/j.diabres.2022.109212_b0165","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-017-0619-2","article-title":"Glycated albumin and its variability as an indicator of cardiovascular autonomic neuropathy development in type 2 diabetic patients","volume":"16","author":"Jun","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.diabres.2022.109212_b0170","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejvs.2010.09.020","article-title":"Use and utility of ankle brachial index in patients with diabetes","volume":"41","author":"Potier","year":"2011","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.diabres.2022.109212_b0175","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.2337\/diacare.28.9.2206","article-title":"An evaluation of the efficacy of methods used in screening for lower-limb arterial disease in diabetes","volume":"28","author":"Williams","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2022.109212_b0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosis.2020.09.026","article-title":"The accuracy of toe brachial index and ankle brachial index in the diagnosis of lower limb peripheral arterial disease: A systematic review and meta-analysis","volume":"315","author":"Herraiz-Adillo","year":"2020","journal-title":"Atherosclerosis"},{"issue":"15","key":"10.1016\/j.diabres.2022.109212_b0185","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.diabres.2022.109212_b0190","first-page":"B21","article-title":"Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients","volume":"23","author":"Shichiri","year":"2000","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.diabres.2022.109212_b0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ahj.2005.09.015","article-title":"Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials","volume":"152","author":"Stettler","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.diabres.2022.109212_b0200","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11892-019-1212-8","article-title":"Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes","volume":"19","author":"Hicks","year":"2019","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.diabres.2022.109212_b0205","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.avsg.2015.11.025","article-title":"Burden of Infected Diabetic Foot Ulcers on Hospital Admissions and Costs","volume":"33","author":"Hicks","year":"2016","journal-title":"Ann Vasc Surg"},{"issue":"8","key":"10.1016\/j.diabres.2022.109212_b0210","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2337\/dc08-9021","article-title":"Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists","volume":"31","author":"Boulton","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2022.109212_b0215","doi-asserted-by":"crossref","unstructured":"Shin JI, Wang D, Fernandes G, Daya N, Grams ME, Golden SH, et al. Trends in Receipt of American Diabetes Association Guideline-Recommended Care Among U.S. Adults With Diabetes: NHANES 2005-2018. Diabetes Care 2021.","DOI":"10.2337\/figshare.14120087"},{"issue":"2","key":"10.1016\/j.diabres.2022.109212_b0220","first-page":"127","article-title":"Comparison of different screening tests for diagnosis of diabetic peripheral neuropathy in Primary Health Care setting","volume":"6","author":"Al-Geffari","year":"2012","journal-title":"Int J Health Sci (Qassim)"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722000249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822722000249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:18:47Z","timestamp":1759173527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822722000249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":44,"alternative-id":["S0168822722000249"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2022.109212","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycated albumin and HbA1c as markers of lower extremity disease inUS adults with and without diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2022.109212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109212"}}